켐포트

비상장계속사업자

chemport INC

김영주

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

켐포트

Business Reg. No. 3148145832 · CEO 김영주

I.Investment Overview

Target켐포트 (3148145832)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명켐포트
영문명chemport INC
대표자김영주
사업자등록번호3148145832
법인등록번호1601110126783
설립일2001.10.27
종업원수72명

V.Shareholders

As of 2025.12.31 · post-deal reflects dilution from the new investment (est.)

Shareholding

  • 김영주25.90%
  • (주)켐포트2.50%
  • Others71.60%
ShareholderRelationSharesPrePost
김영주본인1,561,00025.90%25.90%
(주)켐포트자기주식151,3202.50%2.50%

VI.Key Executives

NameTitleCareer
김영주사장부산대 미생물학과(학사) 전,고합대덕연구소장
이용욱전무KAIST 화학과(석사) 전,고합기술연구소
안영준상무인하대 화학과(석사) 전,고합기술연구소
이수형상무연세대 경영학과(학사) 전,한영회계법인이사(공인회계사)
이정원감사배재대 국제자원개발학과(학사) 전,케이아이씨 공사본부

VII.Workforce

72

Current headcount · 2026.06 as of

VIII.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW182.42023104.72024117.52025
영업이익100M KRW-152023-40.22024-54.72025
순이익100M KRW-202023-33.42024-50.22025
Item202520242023
자산총계332.1억원363.1억원421.1억원
부채총계220.2억원221.9억원246.4억원
자본총계111.9억원141.3억원174.7억원
매출액117.5억원104.7억원182.4억원
영업이익-54.7억원-40.2억원-15억원
순이익-50.2억원-33.4억원-20억원

IX.Financial Ratios

FY2025 basis

-46.53%

영업이익률

-42.72%

순이익률

-4.2%

매출총이익률

-15.11%

ROA

-44.84%

ROE

196.68%

부채비율

59.43%

유동비율

33.71%

자기자본비율

12.19%

매출액증가율

-884원

EPS(원)

X.Audit Opinion

FY-endOpinionAuditor
2025.12.31적정의견신우회계법인
2025.12.31-
2024.12.31적정의견신우회계법인
2024.12.31-
2023.12.31적정신우회계법인
2022.12.31적정신우회계법인

XI.R&D Activity

Fields 화학 > 기타 화학

Keywords 재결정, 분말, 지방산, 트리글리세라이드, 마이크로캡슐

YearProjectsPapersPatents
2014100
2013100
2012100
2011100
2010160

XII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

켐포트 투심보고서 | Alpha Lenz